Global Blood Therapeutics, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 3 Phase 4
Founded: San Francisco CA United States (2012)

Organization Overview

First Clinical Trial
2014
NCT02285088
First Marketed Drug
2019
voxelotor (Oxbryta)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

GBT | Global Blood Therapeutics | Global Blood Therapeutics, Inc. | GLOBAL BLOOD THERAPS